Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis

International Journal of Dermatology

Volumn 51, Issue 10, 2012, Pages 1221-1225

  Esfandiarpour, Iraj ^a   Farajzadeh, Saeedeh ^a   Rahnama, Zahra ^a   Fathabadi, Elahe Arabpoor ^a   Heshmatkhah, Amireh ^a  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGE; AGED; ANAPHYLAXIS; ARTICLE; BURNING SENSATION; CHILD; DIZZINESS; DYSPNEA; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NECROSIS; PAIN; PRURITUS; SECONDARY INFECTION; SEX DIFFERENCE; SKIN LEISHMANIASIS; SPOROTRICHOSIS; URTICARIA; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANAPHYLAXIS; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; ERYTHEMA; FEMALE; HUMANS; INFANT; INJECTIONS, INTRALESIONAL; IRAN; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PAIN; PRURITUS; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 84866557958     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05460.x     Document Type: Article

References (19)

1. Camargo LB, Langoni H. Impact of leishmaniasis on public health. J Venom Anim Toxins Incl Trop Dis 2006; 12: 527-548.
2. Aytekin S, Ertem M, Yaǧdiran O, Aytekin N. Clinico-epidemiologic study of cutaneous leishmaniasis in Diyarbakir, Turkey. Dermatol Online J 2006; 12: 14.
3. Mitropoulos P, Konidas P, Durkin-Konidas M. New World cutaneous leishmaniasis: updated review of current future diagnosis and treatment. J Am Acad Dermatol 2010; 63: 309-322.
4. Sharifi I, Fekri AR, Aflatonian A, et al. Cutaneous leishmaniasis in primary school children in the southeastern Iranian city of Bam, 1994-95. Bull World Health Organ 1998; 76: 289-293.
5. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis 2007; 5: 150-158.
6. Ezzine Sebai N, Mrabet N, Khaled A, et al. Side-effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases [In French]. Tunis Med 2010; 88: 9-11.
7. Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005; 5: 763-774.
8. Esfandiarpour I, Alavi A. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 2002; 41: 521-524.
9. Khatami AR, Firooz AR, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 2007; 57: 335.e1-335.e29.
10. Firooz A, Khatami A, Khamesipour A, et al. Intralesional injection of 2% zinc sulfate solution in the treatment of acute Old World cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial. J Drugs Dermatol 2005; 4: 73-77.
11. World Health Organization. The Leishmaniasis. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1984; 701: 1-140.
12. Faghihi G, Tavakoli-Kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 2003; 28: 13-16.
13. Mutjaba G, Khalid M. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis. Int J Dermatol 1999; 38: 607-609.
14. Oliveira-Neto MP, Schubach A, Mattos M, et al. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil - an area of Leishmania (V.) braziliensis transmission. Int J Dermatol 1997; 36: 463-468.
15. Alkhawajah AM, Larbi E, Al-Gindan Y, et al. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Ann Trop Med Parasitol 1997; 91: 899-905.
16. Akhyani M. Comparative study of cryotherapy and intralesional Glucantime in the treatment of cutaneous leishmaniasis. TUMJ 1997; 55: 29-34.
17. Beheshti M, Ghotbi S, Amirizade S. Therapeutic and adverse effects of Glucantime used for treatment of cutaneous leishmaniasis. Shiraz E Med J 2007; 8: 155-161.
18. Masmoudi A, Maalej N, Boudaya S, et al. Adverse effects of intralesional Glucantime in the treatment of cutaneous leishmaniasis. Med Mal Infect 2006; 36: 226-228.
19. Neves DBJ, Caldas ED, Sampaio RNR. Antimony in plasma and skin of patients with cutaneous leishmaniasis - relationship with side-effects after treatment with meglumine antimoniate. Trop Med Int Health 2009; 14: 1515-1522.